drugset / Trial / NCT05322148

Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization

NCT05322148

Phase 3 Completed 59 enrolled Research Insight LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

The CLEAN Study: Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization-A Prospective Cohort Study of Combination Therapy in the Treatment of Dry Eye

Timeline

Start
2022-06-03
Primary completion
2022-11-17
Completion
2022-11-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide 0.05 %
Comparator Cyclosporine Peptide 0.1 %
Comparator Loteprednol Etabonate Other / unclassified 0.2 %

Indications